ArticleThe journal of allergy and clinical immunology. Global2026
Monitoring adherence and patient-reported outcomes during subcutaneous immunotherapy for house dust mites with the AllergyVax app/web platform.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adherence to treatment and outcome monitoring remain major challenges in allergen immunotherapy. Objective: This study evaluated a digital strategy for monitoring adherence and clinical outcomes of subcutaneous immunotherapy (SCIT) through the AllergyVax mobile and web platform. Methods: This prospective observational study followed 83 patients receiving SCIT through the AllergyVax digital platform for 12 months. Patient-reported outcomes were assessed with the Rhinitis Control Assessment Test and the Asthma Control Test at baseline and predefined follow-up intervals. Both adherence and clinical outcomes were analyzed longitudinally in the same patient group. Methodologic limitations include absence of a control group and relatively short follow-up. Results: The assessment of adherence to SCIT revealed that 84.3% of patients adhered to treatment, 7.2% were recovered adherent patients, and 8.4% dropped out after 12 months of treatment. We compared subgroups by analyzing adherence in patients with rhinitis alone versus those with rhinitis and asthma, as well as between male and female patients. None of the comparisons revealed statistically significant differences between the groups. Conclusions: The digital platform facilitates SCIT management by improving adherence and strengthening patient engagement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.